New drug firm brings jobs boost to town

Macclesfield Express - - BARLOW’S BRIEF - ALEX BELL

AN in­ter­na­tional drugs firm could cre­ate up to 50 jobs in the re­gion af­ter sign­ing up for a space at the BioHub at Alder­ley Park.

The for­mer As­traZeneca site at Alder­ley Edge was bought by Manch­ester Sci­ence Parks and Cheshire East Coun­cil af­ter As­traZeneca an­nounced it would cease its re­search and devel­op­ment work at the site.

It is hoped the ar­rival of He­mato­genix, which aims to cre­ate up to 50 jobs for sci­en­tists within three years with around 15 posts cur­rently avail­able, will at­tract more firms and more jobs to the site.

Mac­cles­field MP David Rut­ley said: “He­mato­genix’s ex­pan­sion onto the Alder­ley Park site rep­re­sents a real vote of con­fi­dence in the sci­ence park. “The new fa­cil­i­ties will be seek­ing to re­cruit from the lo­cal area, which is a tes­ta­ment to the tal­ent and ex­per­tise that our lo­cal com­mu­ni­ties boast. As a mem­ber of the Alder­ley Park Task Force, I am pleased to see this fur­ther pos­i­tive progress.”

The boss of Manch­ester Sci­ence Parks says is work­ing to­wards dou­bling the num­ber of peo­ple work­ing at its sites within the next 10 years.

Chief ex­ec­u­tive Rowena Burns said the molec­u­lar ser­vices firm chose Alder­ley Park above 10 other sites across the UK and Europe.

She said the deal, which was signed for an undis­closed sum, is a sign of things to come and rep­re­sented true for­eign in­vest­ment in the re­gion’s life sciences sec­tor.

She added: “We have scarcely mar­keted this site and al­ready we have this. This is true for­eign di­rect in­vest­ment.

“It opens up mar­kets for us in other parts of the world.”

She added that the biohub in Alder­ley Park had 10 com­pa­nies in it in Oc­to­ber last year, and 68 now run from the base. She said: “We have 3,500 peo­ple em­ployed at MSP and we want to grow that num­ber to 7,000 within the next 10 years.

“There’s am­ple space here for new com­pa­nies to move in.”

The firm fo­cuses on can­cer re­lated test­ing and other molec­u­lar based tests that serve a va­ri­ety of physi­cians in­clud­ing pathol­o­gists, on­col­o­gists, urol­o­gists, gyne­col­o­gists, and car­di­ol­o­gists.

The com­pany’s man­ag­ing direc­tor, pres­i­dent and chief ex­ec­u­tive Dr Hytham Al-Masri, said: “In the first year we will cre­ate up to 15 jobs.

“In the next three years we could cre­ate up to 50 jobs de­pend­ing on how it works out with cer­tain tri­als.

“All those peo­ple will be em­ployed from the fan­tas­tic tal­ent pool that ex­ists in Greater Manch­ester and the north west.

“We are very ex­cited.”

●● Pic­tured left to right are Chris Doherty, vice pres­i­dent of global medicines devel­op­ment at As­traZeneca, Manch­ester Sci­ence Parks chief ex­ec­u­tive Rowena Burns, He­mato­genix man­ag­ing direc­tor, pres­i­dent and chief ex­ec­u­tive Dr Hytham Al-Masri, Chief Fi­nan­cial Of­fi­cer Mo­hamad Al-Masri, Michael Jones, coun­cil leader of Cheshire East Coun­cil and Mac­cles­field MP David Rut­ley.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.